JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Pharmacokinetics Interaction between Cardiotonic Pills and Cilostazol in Rats
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Journal of Life Science
  • Volume 26, Issue 1,  2016, pp.123-128
  • Publisher : Korean Society of Life Science
  • DOI : 10.5352/JLS.2016.26.1.123
 Title & Authors
Pharmacokinetics Interaction between Cardiotonic Pills and Cilostazol in Rats
Kim, Ekyune;
  PDF(new window)
 Abstract
The object of this study was to obtain accurate information about the co-administration effects of cardiotonic pills on the pharmacokinetics of cilostazol were observed as a process of the comprehensive and integrative medicine. Cilostazol is a synthetic anti-platelet and vasodilator agent developed for the treatment of intermittent claudication resulting from peripheral arterial disease. By increasing intracellular cyclic adenosine monophosphate (cAMP), cilostazol induces the activation of protein kinase A, which activates endothelial nitric oxide synthase. In order to evaluate the effect of a single or repeated cardiotonic pill dose on the pharmacokinetics of cilostazol, a single dose of pure_distilled water or a colloidal suspension of distilled water and cardiotonic pills were administered to the control and test groups, respectively. After 30 min, both groups were administered cilostazol. Plasma was collected 30min before administration, and 0.25, 0.5, 0.45, 1, 2, 4, 6, 8, and 24h after the end of cilostazol treatment. We then evaluated the pharmacokinetic changes observed with cilostazol between the control and test groups. No statistically significant differences were observed. These findings demonstrated that a single dose of cardiotonic pills did not affect the pharmacokinetics of cilostazol. The results obtained in this study suggest that co-administration of cardiotonic pills and cilostazol may not affect the bioavailability of cilostazol as a potential drug interaction.
 Keywords
Cilostazol;co-administration;cardiotonic pills;pharmacokinetics;
 Language
Korean
 Cited by
 References
1.
Fowkes, F. G., Housley, E., Cawood, E. H., Macintyre, C. C., Ruckley, C. V. and Prescott, R. J. 1991. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol. 20, 384-392. crossref(new window)

2.
Gresele, P., Momi, S. and Falcinelli, E. 2011. Anti-platelet therapy: phosphodiesterase inhibitors. Br. J. Clin. Pharmacol. 72, 634-646. crossref(new window)

3.
Grant, S. M. and Goa, K. L. 1992. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43, 889-924. crossref(new window)

4.
Horie, Y., Han, J. Y., Mori, S., Konishi, M., Kajihara, M., Kaneko, T., Yamagishi, Y., Kato, S., Ishii, H. and Hibi, T. 2005. Herbal cardiotonic pills prevent gut ischemia/reperfusion-induced hepatic microvascular dysfunction in rats fed ethanol chronically. World J. Gastroenterol. 11, 511-515. crossref(new window)

5.
Kim, E. 2015. Molecular cloning and characterization of Izumo1 gene from bovine testis. J. Anim. Sci. Technol. 57, 16. crossref(new window)

6.
Lee, S. R., Kim, H. O. and Yoo, C. H. 2011. Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer. J. Kor. Surg. Soc. 81, 163-168. crossref(new window)

7.
Muller, B. 1991. Pharmacology of thromboxane A2, prostacyclin and other eicosanoids in the cardiovascular system. Therapie 46, 217-221.

8.
Nishio, S., Matsuura, H., Kanai, N., Fukatsu, Y., Hirano, T., Nishikawa, N., Kameoka, K. and Umetsu, T. 1988. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn. J. Pharmacol. 47, 1-10. crossref(new window)

9.
Nony, P., Ffrench, P., Girard, P., Delair, S., Azoulay, S., Girre, J. P., Dechavanne, M. and Boissel, J. P. 1996. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. Can. J. Physiol. Pharmacol. 74, 887-893. crossref(new window)

10.
Sakai, A., Hori, T., Okuda, T., Matsubara, T., Saitoh, K., Yajima, M. and Nishio, S. 1989. Effect of TRK-100, a prostacyclin analogue, on endotoxin-induced enhancement of blood coagulation in rats. Jpn. J. Pharmacol. 51, 450-454. crossref(new window)

11.
Virgolini, I., Fitscha, P., Linet, O. I., O’Grady, J. and Sinzinger, H. 1990. A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease. Prostaglandins 39, 657- 664.

12.
Wei, X. H., Liu, Y. Y., Li, Q., Yan, L., Hu, B. H., Pan, C. S., Li, Z. X., Chang, X., Fan, J. Y., Zhao, N., Sun, K., Huang, P., Wang, C. S., Fan, T. P. and Han, J. Y. 2013. Treatment with cardiotonic pills ((R)) after ischemia-reperfusion ameliorates myocardial fibrosis in rats. Microcirculation 20, 17-29. crossref(new window)

13.
Zhao, N., Liu, Y. Y., Wang, F., Hu, B. H., Sun, K., Chang, X., Pan, C. S., Fan, J. Y., Wei, X. H., Li, X., Wang, C. S., Guo, Z. X. and Han, J. Y. 2010. Cardiotonic pills, a compound Chinese medicine, protects ischemia-reperfusion-induced microcirculatory disturbance and myocardial damage in rats. Am. J. Physiol. Heart Circ. Physiol. 298, H1166-1176. crossref(new window)